CA3236880A1 - Compounds for treating mds-associated anemias and other conditions - Google Patents

Compounds for treating mds-associated anemias and other conditions Download PDF

Info

Publication number
CA3236880A1
CA3236880A1 CA3236880A CA3236880A CA3236880A1 CA 3236880 A1 CA3236880 A1 CA 3236880A1 CA 3236880 A CA3236880 A CA 3236880A CA 3236880 A CA3236880 A CA 3236880A CA 3236880 A1 CA3236880 A1 CA 3236880A1
Authority
CA
Canada
Prior art keywords
week
subject
weeks
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3236880A
Other languages
English (en)
French (fr)
Inventor
Vanessa BEYNON
Suman Joy Bhatia
Lenny Dang
Melissa L. Dibacco
Varsha V. Iyer
Charles KUNG
Megan LYNCH
Ophelia Qiping Yin
Rolandas URBSTONAITIS
Zhen Xiao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agios Pharmaceuticals Inc
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of CA3236880A1 publication Critical patent/CA3236880A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA3236880A 2021-11-16 2022-11-15 Compounds for treating mds-associated anemias and other conditions Pending CA3236880A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163280069P 2021-11-16 2021-11-16
US63/280,069 2021-11-16
US202263357240P 2022-06-30 2022-06-30
US63/357,240 2022-06-30
PCT/US2022/049969 WO2023091414A1 (en) 2021-11-16 2022-11-15 Compounds for treating mds-associated anemias and other conditions

Publications (1)

Publication Number Publication Date
CA3236880A1 true CA3236880A1 (en) 2023-05-25

Family

ID=84887868

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3236880A Pending CA3236880A1 (en) 2021-11-16 2022-11-15 Compounds for treating mds-associated anemias and other conditions

Country Status (11)

Country Link
US (1) US20250108049A1 (https=)
EP (1) EP4433057A1 (https=)
JP (1) JP2024543345A (https=)
KR (1) KR20240107326A (https=)
AU (1) AU2022390088A1 (https=)
CA (1) CA3236880A1 (https=)
CL (1) CL2024001431A1 (https=)
IL (1) IL312679A (https=)
MX (1) MX2024005852A (https=)
TW (1) TW202329935A (https=)
WO (1) WO2023091414A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202509043A (zh) * 2023-05-15 2025-03-01 美商阿吉歐斯製藥公司 ２－（（１ｈ－吡唑－３－基）甲基）－６－（（６－胺基吡啶－２－基）甲基）－４－甲基－４，６－二氫－５ｈ－噻唑基［５＇，４＇：４，５］吡咯并［２，３－ｄ］嗒𠯤－５－酮之結晶形式
WO2026076363A1 (en) 2024-10-04 2026-04-09 Agios Pharmaceuticals, Inc. Compounds for treating mds-associated anemias and other conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI598337B (zh) 2009-06-29 2017-09-11 阿吉歐斯製藥公司 治療化合物及組成物
CA2989111C (en) 2015-06-11 2023-10-03 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators
TWI796353B (zh) 2017-08-15 2023-03-21 美商阿吉歐斯製藥公司 丙酮酸激酶調節劑及其用途
KR102777452B1 (ko) 2017-11-22 2025-03-10 아지오스 파마슈티컬스 아이엔씨. N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의결정 형태
WO2020237047A1 (en) 2019-05-22 2020-11-26 Agios Pharmaceuticals, Inc. Crystalline salt forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

Also Published As

Publication number Publication date
JP2024543345A (ja) 2024-11-21
EP4433057A1 (en) 2024-09-25
TW202329935A (zh) 2023-08-01
CL2024001431A1 (es) 2024-10-25
US20250108049A1 (en) 2025-04-03
AU2022390088A1 (en) 2024-05-09
MX2024005852A (es) 2024-05-28
WO2023091414A1 (en) 2023-05-25
KR20240107326A (ko) 2024-07-09
IL312679A (en) 2024-07-01

Similar Documents

Publication Publication Date Title
JP6852073B2 (ja) 悪性病変を処置する方法
KR102400737B1 (ko) 치료적으로 활성인 화합물의 약제학적 조성물
CN111107851B (zh) 组合及其用于治疗癌症的用途
AU2016340087C1 (en) Combination therapy for treating malignancies
TW202521120A (zh) 藥物組合物及其應用
US20250108049A1 (en) Compounds for treating mds-associated anemias and other conditions
UA123400C2 (uk) Комбінована терапія для лікування злоякісних пухлин
CA2816957A1 (en) Compositions and methods for treating myelofibrosis
US9877963B2 (en) GlyT1 inhibitors for use in the treatment of hematological disorders
RU2734930C2 (ru) Режимы дозирования мелфлуфена для раковых заболеваний
KR102136017B1 (ko) 만성 기침의 치료를 위한 오베피탄트
TW201217361A (en) Method of treating abnormal cell growth
AU2025271046A1 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
CN103429239A (zh) 增加网织红细胞血红蛋白含量的方法
CA3096156A1 (en) Use of inhibitors of bcr-abl mutants for the treatment of cancer
KR20210084442A (ko) 포도막 흑색종 치료를 위한 병용 요법
JP7493503B2 (ja) Ｍｃｌ－１阻害剤とミドスタウリンとの組み合わせ、その使用及び医薬組成物
JP2025015727A (ja) ｐ－ボロノフェニルアラニンを含有する注射液剤
EA050684B1 (ru) Соединения для лечения анемий и других патологических состояний, ассоциированных с mds
DK2855487T3 (en) Compounds for the treatment of ischemia-reperfusion-related diseases
TW202440116A (zh) 組合療法
CN118382439A (zh) 用于治疗mds相关贫血和其他病症的化合物
JP7618235B2 (ja) ｐ－ボロノフェニルアラニンを含有する注射液剤の析出防止方法
WO2026076363A1 (en) Compounds for treating mds-associated anemias and other conditions
JPWO2006004028A1 (ja) キノロン含有医薬組成物

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241108

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241108

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241108

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20241122

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241122

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251107

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251107

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260423